Trial · NCT03685747
Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
NCT03685747, Phase 1, Completed, Thomas Jefferson University; results first posted 2022-03-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis. Trials, record NCT03685747. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03685747
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
- NCT number
- NCT03685747
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 4 participants, actual
- Lead sponsor
- Thomas Jefferson University
- Conditions
- Peritoneal Dialysis-associated Peritonitis
- Interventions
- Vancomycin
- First posted
- 2018-09-26
- Last updated
- 2022-03-03
- Results first posted
- 2022-03-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Total Plasma Concentration (Cmax) | Day: 1 | Total systemic plasma concentration following 12-hour dwell |
| Primary | Time to Maximum Plasma Concentration (Tmax) | Day: 1 | Time (hours) to achieve the maximum plasma concentration |
| Primary | Area Under the Concentration-time Curve (AUC0-inf) | Days: 1-7 | AUC based on vancomycin plasma concentrations |
| Primary | Total Body Clearance (CLtotal) | Days: 1-7 | Total vancomycin plasma vancomycin clearance |
| Primary | Dialytic Clearance | Days: 1-7 | Vancomycin clearance from peritoneal dialysis |
| Secondary | Adverse Events | Days: 1-7 | Any adverse events throughout entirety of study as assessed by physician-investigator |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Total Plasma Concentration (Cmax) | Day: 1 | mg/L | MEAN | |
| PRIMARY | Time to Maximum Plasma Concentration (Tmax) | Day: 1 | hours | MEDIAN | |
| PRIMARY | Area Under the Concentration-time Curve (AUC0-inf) | Days: 1-7 | hr x mg/L | MEAN | |
| PRIMARY | Total Body Clearance (CLtotal) | Days: 1-7 | mL/min | MEAN | |
| PRIMARY | Dialytic Clearance | Days: 1-7 | mL/min | MEAN | |
| SECONDARY | Adverse Events | Days: 1-7 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Total Plasma Concentration (Cmax) | Vancomycin | 28.7 | Standard Deviation 4.9 | mg/L | |
| Time to Maximum Plasma Concentration (Tmax) | Vancomycin | 14.4 | Full Range 13.8 to 15 | hours | |
| Area Under the Concentration-time Curve (AUC0-inf) | Vancomycin | 2589.9 | Standard Deviation 365.6 | hr x mg/L | |
| Total Body Clearance (CLtotal) | Vancomycin | 7.2 | Standard Deviation 1.3 | mL/min | |
| Dialytic Clearance | Vancomycin | 11.1 | Standard Deviation 4.3 | mL/min | |
| Adverse Events | Vancomycin | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vancomycin | 4 | |
| Overall Study | COMPLETED | Vancomycin | 4 | |
| Overall Study | NOT COMPLETED | Vancomycin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vancomycin | 0 | 4 |
| Total, other adverse events | Vancomycin | 0 | 4 |
| Total, serious adverse events | Vancomycin | 0 | 4 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34755479 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03685747
GET https://conductscience.org/api/trials/v1/NCT03685747/registered